Answers are grounded in this paper and cite their sources.
Buntanetap is an orally available small RNA targeting molecule that inhibits the translation of multiple neurotoxic aggregating proteins, including amyloid precursor protein (APP) and Tau. It has been evaluated in over 1200 participants, including healthy volunteers, patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD), and has shown a favorable safety and tolerability profile. We evaluated the safety and efficacy of buntanetap in treating early PD patients with MMSE ≥ 20 in this 6-month randomized double-blind dose-ranging study. A total of 523 early PD patients were enrolled In the US and in 6 different countries in the European Union (Germany, Spain, Italy, Poland, Hungary) across a total of 67 sites (42 in the United States and 25 in the European Union). Patients were given either 10, 20 mg buntanetap or placebo. Buntanetap had a favorable safety profile. The study did not meet its primary endpoints (MDS-UPDRS Part II). However, in a post-hoc analysis, buntanetap improved patients’ cognition. In amyloid-positive PD patients with mild cognitive impairment and mild dementia, buntanetap not only demonstrated nominally statistically significant dose-dependent cognitive benefits but also showed potential improvement in all MDS-UPDRS and other scales tested. These findings were supported by biomarker evidence of target engagement. Further evaluations of buntanetap in this patient population are warranted.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: